Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 3/2019

01-06-2019 | Sudden Cardiac Death

Synthetic Cannabinoids and Cardiac Arrhythmia Risk: Review of the Literature

Authors: Hayriye Mihrimah Ozturk, Ertan Yetkin, Selcuk Ozturk

Published in: Cardiovascular Toxicology | Issue 3/2019

Login to get access

Abstract

Synthetic cannabinoids (SCBs) are widely used recreational substances especially among adults. Although they have been considered as safe during the marketing process, our knowledge about their adverse effects has evolved since years. SCBs are associated with various cardiac events including acute myocardial infarction and sudden cardiac death. There is also growing evidence that SCBs are associated with cardiac arrhythmia development both in acute and chronic exposure. SCBs have been shown to be associated with both supraventricular and ventricular arrhythmias. However, the exact mechanism of the SCB related arrhythmia remains unknown. Understanding the exact association and possible mechanisms may help us to identify high risk patients at an early stage and to develop treatment modalities to prevent or reverse the arrhythmic effects of SCBs.
Literature
1.
Mills, B., Yepes, A., & Nugent, K. (2015). Synthetic cannabinoids. The American Journal of the Medical Sciences, 350, 59–62.CrossRefPubMed
2.
Cohen, K., & Weinstein, A. (2018). The effects of cannabinoids on executive functions: Evidence from cannabis and synthetic cannabinoids—a systematic review. Brain Sciences, 8, 40.CrossRefPubMedCentral
3.
Freund, S. A., & Banning, A. S. (2017). Synthetic cannabinoids: A review of the clinical implications of a new drug of choice. Journal of the American Academy of PAs, 30, 1–4.
4.
Le Boisselier, R., Alexandre, J., Lelong-Boulouard, V., & Debruyne, D. (2017). Focus on cannabinoids and synthetic cannabinoids. Clinical Pharmacology and Therapeutics, 101, 220–229.CrossRefPubMed
5.
Zanda, M. T., & Fattore, L. (2018). Old and new synthetic cannabinoids: lessons from animal models. Drug Metabolism Reviews, 50, 54–64.CrossRefPubMed
6.
7.
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018). Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly. Nature Reviews Cardiology, 15, 151.CrossRefPubMed
8.
McKeever, R. G., Vearrier, D., Jacobs, D., LaSala, G., Okaneku, J., & Greenberg, M. I. (2015). K2–not the spice of life; Synthetic cannabinoids and ST elevation myocardial infarction: a case report. Journal of Medical Toxicology, 11, 129–131.CrossRefPubMed
9.
Andonian, D. O., Seaman, S. R., & Josephson, E. B. (2017). Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication—A case series. The American Journal of Emergency Medicine, 35, 940-e945–940-e946.CrossRef
10.
Mukhopadhyay, P., Rajesh, M., Batkai, S., Patel, V., Kashiwaya, Y., Liaudet, L., et al. (2009). CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovascular Research, 85, 773–784.CrossRefPubMedPubMedCentral
11.
Montecucco, F., & Di Marzo, V. (2012). At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends in Pharmacological Sciences, 33, 331–340.CrossRefPubMed
12.
Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58, 389–462.CrossRefPubMedPubMedCentral
13.
Steffens, S., & Pacher, P. (2012). Targeting cannabinoid receptor CB2 in cardiovascular disorders: Promises and controversies. British Journal of Pharmacology, 167, 313–323.CrossRefPubMedPubMedCentral
14.
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014). Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12–41.CrossRefPubMed
15.
Davis, C., & Boddington, D. (2015). Teenage cardiac arrest following abuse of synthetic cannabis. Heart, Lung and Circulation, 24, e162–e163.CrossRefPubMed
16.
Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24, 598–601.CrossRefPubMed
17.
18.
Byrnes, T. J., & Costantini, O. (2017). Tachyarrhythmias and bradyarrhythmias: Differential diagnosis and initial management in the primary care office. Medical Clinics, 101, 495–506.PubMed
19.
Dilaveris, P., Batchvarov, V., Gialafos, J., & Malik, M. (1999). Comparison of different methods for manual P wave duration measurement in 12-lead electrocardiograms. Pacing and Clinical Electrophysiology, 22, 1532–1538.CrossRefPubMed
20.
Yetkin, E. (2018). Diagnostic challenges in supraventricular tachycardia: anticipating value of natriuretic peptides. Cardiovascular Endocrinology & Metabolism, 7, 34–36.CrossRef
21.
Yetkin, E. (2016). Symptoms in supraventricular tachycardia: Is it simply a manifestation of increased heart rate? Medical Hypotheses, 91, 42–43.CrossRefPubMed
22.
Doğan, S., Akman, C., Yılmaz, A., Kalafat, U. M., & Ocak, T. (2016). A hypothermic case with giant Osborn waves and atrial fibrillation after using synthetic cannabinoid. The Anatolian Journal of Cardiology, 16, E1.CrossRefPubMed
23.
Efe, T. H., Felekoglu, M. A., Cimen, T., & Dogan, M. (2017). Atrial fibrillation following synthetic cannabinoid abuse. Turk Kardiyol Dern Ars, 45, 362–364.PubMed
24.
25.
Lapoint, J., James, L., Moran, C., Nelson, L., Hoffman, R., & Moran, J. (2011). Severe toxicity following synthetic cannabinoid ingestion. Clinical Toxicology, 49, 760–764.CrossRefPubMed
26.
Lam, R. P. K., Tang, M. H. Y., Leung, S. C., Chong, Y. K., Tsui, M. S. H., & Mak, T. W. L. (2017). Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: A case report with quantitative analysis of serum drug concentrations. Clinical Toxicology, 55, 662–667.CrossRefPubMed
27.
28.
Westin, A. A., Frost, J., Brede, W. R., Gundersen, P. O. M., Einvik, S., Aarset, H., et al. (2015). Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. Journal of Analytical Toxicology, 40, 86–87.PubMed
29.
Sunbul, E. A., Sunbul, M., Terzi, A., Calli, S., Koca, E., Bilici, R., et al. (2016). The effect of synthetic cannabinoids on P-wave dispersion: An observational study. Medical Principles and Practice, 25, 483–487.CrossRefPubMedPubMedCentral
30.
Ozturk, H. M., Erdogan, M., Alsancak, Y., Yarlioglues, M., Duran, M., Boztas, M. H., et al. (2018). Electrocardiographic alterations in patients consuming synthetic cannabinoids. Journal of Psychopharmacology, 32, 296–301.CrossRefPubMed
31.
van Weerd, J. H., & Christoffels, V. M. (2016). The formation and function of the cardiac conduction system. Development, 143, 197–210.CrossRefPubMed
32.
Roberts-Thomson, K. C., Lau, D. H., & Sanders, P. (2011). The diagnosis and management of ventricular arrhythmias. Nature Reviews Cardiology, 8, 311.CrossRefPubMed
33.
Von Der Haar, J., Talebi, S., Ghobadi, F., Singh, S., Chirurgi, R., Rajeswari, P., et al. (2016). Synthetic cannabinoids and their effects on the cardiovascular system. The Journal of Emergency Medicine, 50, 258–262.CrossRef
34.
Nacca, N., Schult, R., Loflin, R., Weltler, A., Gorodetsky, R., Kacinko, S., et al. (2018). Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer. The Journal of Emergency Medicine, 55, 788–791.CrossRefPubMed
35.
Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Longworth, M., et al. (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6, 1546–1559.CrossRefPubMed
36.
Yamanoglu, A., Celebi Yamanoglu, N. G., Evran, T., & Sogut, O. (2018). How much can synthetic cannabinoid damage the heart? A case of cardiogenic shock following resistant ventricular fibrillation after synthetic cannabinoid use. Journal of Clinical Ultrasound, 46, 605–609.CrossRefPubMed
37.
38.
Yun, J., Yoon, K. S., Lee, T.-H., Lee, H., Gu, S. M., Song, Y. J., et al. (2016). Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicology Research, 5, 1663–1671.CrossRefPubMedPubMedCentral
39.
Lindsay, A. C., Foale, R. A., Warren, O., & Henry, J. A. (2005). Cannabis as a precipitant of cardiovascular emergencies. International Journal of Cardiology, 104, 230–232.CrossRefPubMed
40.
41.
Kaschina, E. (2016). Cannabinoid CB1/CB2 receptors in the heart: Expression, regulation, and function, in cannabinoids in health and disease. InTech.
42.
Al Kury, L. T., Voitychuk, O. I., Yang, K. H. S., Thayyullathil, F. T., Doroshenko, P., Ramez, A. M., et al. (2014). Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. British Journal of Pharmacology, 171, 3485–3498.CrossRefPubMedPubMedCentral
43.
Foadi, N., Berger, C., Pilawski, I., Stoetzer, C., Karst, M., Haeseler, G., et al. (2014). Inhibition of voltage-gated Na + channels by the synthetic cannabinoid ajulemic acid. Anesthesia and Analgesia, 118, 1238–1245.CrossRefPubMed
44.
Krylatov, A., Maslov, L., Ermakov, S. Y., Lasukova, O., Barzakh, E., Crawford, D., et al. (2007). Significance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart. Biology Bulletin, 34, 28–35.CrossRef
45.
Li, Q., Ma, H. J., Zhang, H., Qi, Z., Guan, Y., & Zhang, Y. (2009). Electrophysiological effects of anandamide on rat myocardium. British Journal of Pharmacology, 158, 2022–2029.CrossRefPubMedPubMedCentral
46.
Barana, A., Amoros, I., Caballero, R., Gomez, R., Osuna, L., Lillo, M. P., et al. (2009). Endocannabinoids and cannabinoid analogues block cardiac hKv1. 5 channels in a cannabinoid receptor-independent manner. Cardiovascular Research, 85, 56–67.CrossRef
47.
Sheridan, R. D., Turner, S. R., Cooper, G. J., & Tattersall, J. E. (2005). Effects of seven drugs of abuse on action potential repolarisation in sheep cardiac Purkinje fibres. European Journal of Pharmacology, 511, 99–107.CrossRefPubMed
48.
Ford, B. M., Tai, S., Fantegrossi, W. E., & Prather, P. L. (2017). Synthetic pot: Not your grandfather’s marijuana. Trends in Pharmacological Sciences, 38, 257–276.CrossRefPubMedPubMedCentral
49.
Guzel, D., Yazici, A. B., Yazici, E., & Erol, A. (2017). Alterations of the hematologic cells in synthetic cannabinoid users. Journal of Clinical Laboratory Analysis, 31, e22131.CrossRef
50.
51.
İzci, F., İzci, V., İzci, S., Çiftçi, E., Koç, Mİ., Bilici, R., et al. (2015). Intravenous lipid emulsion as a treatment of sinus tachycardia induced by synthetic cannabinoid intoxication: Two case reports. Bağımlılık Dergisi-Journal of Dependence, 16, 210–213.
Metadata
Title
Synthetic Cannabinoids and Cardiac Arrhythmia Risk: Review of the Literature
Authors
Hayriye Mihrimah Ozturk
Ertan Yetkin
Selcuk Ozturk
Publication date
01-06-2019
Publisher
Springer US
Published in
Cardiovascular Toxicology / Issue 3/2019
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-019-09522-z

Other articles of this Issue 3/2019

Cardiovascular Toxicology 3/2019 Go to the issue

OriginalPaper

MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte

OriginalPaper

Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts

OriginalPaper

Methoxetamine Induces Cytotoxicity in H9c2 Cells: Possible Role of p21 Protein (Cdc42/Rac)-Activated Kinase 1

OriginalPaper

Cyclosporine Metabolites’ Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens

OriginalPaper

Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle

OriginalPaper

Limb Blood Flow Restriction Plus Mild Aerobic Exercise Training Protects the Heart Against Isoproterenol-Induced Cardiac Injury in Old Rats: Role of GSK-3β

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits